schedule I

The Drug Enforcement Administration (DEA) has announced a 10-day hearing to deliberate on the potential ban of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). As reported by Green Market Report, the hearing, scheduled to run from...

Bright Green Corporation (NASDAQ:BGXX) announced on Thursday that it has received final approval from the New Mexico Board of Pharmacy and the DEA to register, license and authorize Schedule I and Schedule II plant-based drugs and active pharmaceutical ingredients for research, production, and...